Schnapp P, Hermann H, Cernak P, Kahay J
Curr Med Res Opin. 1987;10(6):407-13. doi: 10.1185/03007998709111110.
A single-blind, placebo-controlled study was carried out to evaluate the suitability of slow-release nifedipine as antihypertensive monotherapy for the elderly. After a wash-out period, nifedipine slow-release tablets (20 mg twice daily) followed by matching placebo were administered, each for 4 weeks, to 23 patients over 60 years of age with essential mild to moderate hypertension. Nifedipine significantly reduced the systolic and diastolic blood pressure, and increased the pulse rate in both supine and upright positions. The pre-treatment supine systolic blood pressure proved the best single predictor of the blood pressure decreases in both positions. The decrease in mean arterial blood pressure correlated significantly with the nifedipine plasma concentration. Significant biochemical changes were observed with nifedipine, namely increased serum K+ level and decreased levels of serum Na+, cholesterol and triglycerides. Side-effects in general were mild and transient; nevertheless, 3 patients dropped out because of severe leg oedema.
开展了一项单盲、安慰剂对照研究，以评估缓释硝苯地平作为老年患者抗高血压单一疗法的适用性。经过洗脱期后，对23名60岁以上的原发性轻至中度高血压患者给予缓释硝苯地平片（每日两次，每次20毫克），随后给予匹配的安慰剂，各治疗4周。硝苯地平显著降低了仰卧位和直立位的收缩压和舒张压，并增加了心率。治疗前仰卧位收缩压被证明是两个体位血压下降的最佳单一预测指标。平均动脉血压的下降与硝苯地平血浆浓度显著相关。硝苯地平治疗后观察到显著的生化变化，即血清钾水平升高，血清钠、胆固醇和甘油三酯水平降低。总体而言，副作用轻微且短暂；然而，有3名患者因严重腿部水肿而退出研究。
